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ARTICLE
Single-nucleotide polymorphisms in the P2X7 receptor
gene are associated with post-menopausal bone loss
and vertebral fractures
Niklas R Jørgensen*,1,2,3, Lise B Husted4, Kristen K Skarratt5, Leanne Stokes5, Charlotte L Tofteng2,
Torben Kvist1, Jens-Erik B Jensen2, Pia Eiken6, Kim Brixen7, Stephen Fuller5, Rory Clifton-Bligh5,
Alison Gartland8, Peter Schwarz1, Bente L Langdahl4 and James S Wiley5
The purinergic P2X7 receptor has a major role in the regulation of osteoblast and osteoclast activity and changes in receptor
function may therefore affect bone mass in vivo. The aim of this study was to determine the association of non-synonymous
single-nucleotide polymorphisms in the P2RX7 gene to bone mass and fracture incidence in post-menopausal women. A total of
1694 women (aged 45–58) participating in the Danish Osteoporosis Prevention Study were genotyped for 12 functional P2X7
receptor variants. Bone mineral density was determined at baseline and after 10 years. In addition, vertebral fracture incidence
was documented at 10 years. We found that the rate of bone loss was clearly associated with the Arg307Gln amino acid
substitution such that individuals heterozygous for this polymorphism had a 40% increased rate of bone loss. Furthermore,
individuals carrying the Ile568Asn variant allele had increased bone loss. In contrast, the Gln460Arg polymorphism was
associated with protection against bone loss. The Ala348Thr polymorphism was associated with a lower vertebral fracture
incidence 10 years after menopause. Finally, we developed a risk model, which integrated P2RX7 genotypes. Using this model,
we found a clear association between the low-risk (high-P2X7 function) alleles and low rate of bone loss. Conversely, high-risk
(reduced P2X7 function) alleles were associated with a high rate of bone loss. In conclusion, an association was demonstrated
between variants that reduce P2X7 receptor function and increased rate of bone loss. These data support that the P2X7 receptor
is important in regulation of bone mass.
European Journal of Human Genetics (2012) 20, 675–681; doi:10.1038/ejhg.2011.253; published online 25 January 2012
Keywords: osteoporosis; vertebral fracture; P2X7; polymorphism; purinergic
INTRODUCTION
Osteoporosis is a widespread systemic disorder characterized by
decreased bone mass and increased risk of fracture. In Europe, the
incidence of osteoporosis is increasing exponentially.1 Genetic factors
have a role in the regulation of bone mass.2 Changes in bone turnover
and the occurrence of fractures are associated with a number of single-
nucleotide polymorphisms (SNPs) in genes coding for bone-related
proteins, but disappointingly the effect sizes have been lower than
anticipated.3 Osteoporosis is a multi-factorial disease that results from
a combination of genetic, environmental and other risk factors, such
as tobacco use, sedentary lifestyle, low calcium intake, low body
weight, certain medications (glucocorticoids), and so on, that affect
peak bone mass and rate of bone loss.
The P2X7 purinergic receptor belongs to a family of ligand-gated
cation channels.4 In contrast to other P2X receptors, prolonged
activation with ligand induces formation of a pore permeable to
cations up to 900 Da.5 P2X7 is expressed primarily by cells of the
hematopoietic and immune system,6–10 osteoclasts,11 osteoblasts12,13
and osteocytes.14 Activation of P2X7 has been shown to induce
membrane blebbing (in osteoclasts),15 metalloproteinase activation
(in lymphocytes),16 and following prolonged activation, apoptosis and
cell death (osteoclasts).17 In addition, P2X7 activation is a major
stimulus for formation and activation of the inflammasome 18 and
release of interleukin (IL)-1a and IL-1b.10,19,20 This is particularly
relevant in relation to post-menopausal bone loss, where estrogen
depletion results in increased production and release of IL-1, and
subsequently osteoclast formation and bone resorption.21
It has been demonstrated that P2X7 is involved in mechanically
induced signalling between osteoblasts and osteoclasts,14 as well as with
osteoclast survival.12,17,22 Furthermore, it has been shown to couple to
NF-kB in osteoclasts.23 In a P2X7 knock-out model, P2X7-null mice
have decreased bone mass24,25 and decreased responses to mechanical
stimulation of the bones,26 supporting a role for the P2X7 receptor in
skeletal mechanotransduction. Thus, defects in normal P2X7 receptor
function in humans could potentially have detrimental effects on bone
mass, quality and skeletal resistance to mechanical stress.
The P2X7 receptor gene, P2RX7, is located on chromosome 12q24.
It is highly polymorphic with 40 coding variants reported in the latest
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build 132 of dbSNP database with more than a dozen variants
characterized for their effect on function.27 At least eight non-synon-
ymous variants in P2RX7 confer loss-of-function in the P2X7 signal-
ling pathway. Three are uncommon (1–3% minor allele frequency
(MAF)) but give rise to severe functional defects.28 In particular, one
of these three variants, Arg307Gln, which is located in the ATP
binding pocket, dramatically alters receptor function by reducing
the affinity of agonist binding.29 Only two variants (His155Tyr and
Ala348Thr) have been shown to confer gain-of-function. However,
while the inheritance of the Gln460Arg minor allele in isolation causes
insignificant loss-of-function, the 460-Arg is nearly always co-inher-
ited with 155Tyr and 348Thr and thus is a marker of the major gain-
of-function haplotype of P2RX7 in Caucasians.30
In this study, we performed an association analysis of non-synon-
ymous variants in P2RX7 and changes in bone mineral density (BMD)
and fracture rates over 10 years in post-menopausal women. A risk
model based on the functional effects of the individual variants on
receptor function showed a clear association to the regulation of bone
mass. Thus, the P2X7 receptor is important in regulating BMD in the
ageing human skeleton.
PARTICIPANTS AND METHODS
Study participants
The study population consisted of healthy, post-menopausal Danish women
included in the Danish Osteoporosis Prevention Study (DOPS). They were
enrolled 3–24 months after menopause and aged 45–58 years at inclu-
sion. The recruitment procedure and study design have been described
previously.31 In brief, DOPS is a prospective multi-center trial investi-
gating the preventive effect of hormone replacement therapy (HRT) on the
development of osteoporotic fractures. A total of 2016 women were included
and they were allocated to a randomized and a non-randomized arm. In both
arms, study participants were allocated to either HRT or non-HRT with a
randomized open design in the randomized arm while participants included
in the non-randomized arm were given the possibility of choosing between
HRT and non-HRT. From the total number of 2016 women, 1795 gave
informed consent to donate DNA, which was stored at 80 1C. However,
as genotyping was performed in duplicate at two sites, and individuals
where discrepant results were found, were excluded from the analyses a
total of between 1651 and 1694 individuals were available for analysis for the
individual variants.
To determine the association between the individual genotypes and BMD
and fracture rate in HRT naı¨ve women and the response to HRT, the 5 and
10 years longitudinal analyses were performed separately for the two groups.
At 5/10 years, 876/768 in the HRT-naı¨ve group and 418/121 in the HRT-group
were evaluable. The main reason for the decrease in evaluable individuals is that
study participants were allowed to change treatment during the course of the
study. All procedures involving patients and patient materials were approved by
the Danish Ethics Committee (approval #1990/1821), and all participants were
recruited after obtaining informed consent.
Genotyping
Non-synonymous P2RX7 variants, which were selected for a known effect on
P2X7 receptor function, were analyzed using TaqMan allelic discrimination
assays (Department of Endocrinology at Aarhus University Hospital, Aarhus,
Denmark) and a homogeneous mass extension assay (HME) at the Australian
Genome Research Facility (St Lucia, Queensland). Samples that failed HME
were re-analyzed using restriction enzyme digestion of appropriate PCR
products or by Taqman assay as previously described.32,33 Homogenous mass
extension method failed in 3–4% of the samples and for these samples
genotyping was repeated using real-time PCR. To determine accuracy,
genotyping results were compared between the two genotyping methods.
Discrepancies were found for 79 individuals at one or more variants.
There was a discrepancy rate between the two genotyping methods of o1%
and all discrepant results were removed from the final analysis. In 40
individuals, genotyping failed for eight or more variants, and these subjects
were excluded from the analyses. Haplotype analysis was performed using
Phase 2.0 software.34
Biochemistry
At baseline, blood samples were collected in the morning after an overnight
fast. Serum was isolated and stored at 80 1C for later analysis. Bone-specific
alkaline phosphatase (U/l) was lectin-precipitated and analyzed using spectro-
photometry with an intraassay coefficient of variation (CV) of 8% and an
interassay CV of 25%. Serum osteocalcin was analyzed by radio-immuno assay
as described previously.31 Intraassay CV was 5% and interassay CV was 10%.
Hydroxyproline (OHP), was measured using fasting second void urine and
analyzed by spectrophotometry according to the manufacturer’s instructions
(Organon Teknika, Boxtel, The Netherlands). Values were expressed as a ratio
relative to creatinine (Cr) excretion (OHP/Cr, mmol/mmol).
Bone mass measurements
At inclusion, and after 5 and 10 years, BMD (g/cm2) was assessed using dual-
energy X-ray absorptiometry for all study participants. BMD was determined at
the lumbar spine, the hip and the femoral neck using cross-calibrated Hologic
QDR-1000/W and Hologic QDR-2000 densitometers (Hologic Inc., Waltham,
MA, USA).
Fracture determination
At inclusion, and after 5 and 10 years, X-rays of the vertebral spine were
obtained as lateral projections covering T4 to L5. The presence of vertebral
fractures was evaluated by a trained radiologist and a fracture was defined as
420% reduction in the height at the anterior, middle or posterior of the
vertebrae. Of the 1680 having a vertebral X-ray performed at the 10 years visit,
143 were diagnosed as having one or more vertebral fractures. After 10 years,
genotypes were available for 799 individuals in the non-HRT group included in
the fracture study, of which 71 had sustained one or more vertebral fractures.
Of these, 51 subjects had one vertebral fracture and the remaining 20 had41.
In the HRT group, genotypes were available for 124 individuals. Six had one or
more vertebral fractures diagnosed on X-ray, and of these three had one
fracture and three had more than one fracture.
Statistical analysis
Distribution of genotype frequencies was tested for adherence to Hardy–
Weinberg equilibrium (HWE) using the w2-test and Fisher’s exact test. Differences
in BMD or rate of bone loss were tested by one-way analysis of variance (ANOVA)
after testing for normal distribution of the data. Results are expressed as
mean±SD. Differences in covariates between genotypes were tested by ANOVA
and Kruskal–Wallis test. The influence of covariates on baseline BMD values
were tested using the general linear model procedure for covariance analysis
(ANCOVA) and BMD values were corrected for age, body mass index (BMI),
and time following menopause. For fracture analysis, differences in fracture
incidences were tested using the w2-test. For all analyses, P-values o0.05 were
considered statistically significant. All statistic calculations were performed
using the SPSS statistical software, version 11.5 (SPSS Inc., Chicago, IL, USA).
RESULTS
P2X7 genotypes
The study population was genotyped for 12 different non-synon-
ymous SNPs in the gene coding for the P2X7 receptor. The variants
were selected based on published effects on receptor function
(Table 1). Furthermore, the MAFs are shown in Table 1. All variants
were in HWE, except for the Gly150Arg (Po0.001).
Baseline characteristics at menopause of the P2X7 genotypes
First, age, height, BMI and bone markers were compared for the
individual genotypes. No statistically significant differences were
found between genotypes. Next, baseline values of BMD were com-
pared. Interestingly, significant differences between genotypes were
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found for both the Val76Ala and the Gln460Arg polymorphism
(Supplementary Material Table). However, after correcting for multi-
ple analyses, only the Gln460Arg polymorphism remained signifi-
cantly associated to BMD at the femoral neck (P¼0.01) with the
homozygotes for the variant alleles having the higher BMD. Although
not significant, this trend was also present for the two other sites of
measurement.
P2X7 genotype and bone loss over 5 and 10 years after menopause
An accelerated bone loss takes place after menopause and the rate of
bone loss was expressed as change of BMD per year over 0–5 and 0–10
years for each genotype of the 12 functional variants in P2RX7. For
women not treated with HRT at any time, BMD loss at the hip was
greatest in those heterozygous for Arg307Gln (Figure 1a and Table 2).
A similar trend was observed in both lumbar spine and femoral neck
at 0–5 and 0–10 years. In subjects receiving HRT treatment, rates of
bone loss were much reduced in all P2X7 genotypes. However, even in
this HRT group, the variant allele Arg307Gln, was still associated with
more bone loss over 0–5 years than those who were wild type for this
allele (Figure 1b). Owing to low numbers in the individual genotype
groups, it was not possible to make similar analyses for the 0–10 year
bone loss. These results suggest a major effect of the P2X7 loss-of-
function 307-Arg allele in accelerating bone loss in post-menopausal
women.
Another functional variant in P2RX7 had significant effects on the
rate of bone loss. The Ile568Asn allele was significantly associated to
the rate of bone loss from 0 to 5 years after menopause in the non-
HRT group (Figure 1c) with two subjects homozygous for the variant
allele (AA) clearly having the highest rate of bone loss of all the P2X7
genotypes. However, analysis of the rate of bone loss from 0 to 10
years after menopause showed that this variant was not significantly
associated to the bone loss, although numerically the trends were the
same as from 0 to 5 years (data not shown). To demonstrate that the
findings were not due to differences in basic parameters at baseline for
the subgroups not on HRT at 5 and 10 years, we compared the
baseline values for age, height, BMI and BMD, and found no
differences between genotypes for those two subgroups.
As the frequency of the rare allele for the four polymorphisms
Val76Ala, Gly150Arg, Thr357Ser and Ile568Asn are very low, we per-
formed the above analyses again after grouping individuals carrying the
rare allele (heterozygotes and homozygotes for the rare allele). However,
no additional associations could be demonstrated (not shown).
P2X7 genotype and fracture risk after 5 and 10 years after
menopause
We examined the distribution of vertebral fractures for the 12 P2X7
variants. In a previous analysis of our data, the common Glu496Ala
variant was associated with vertebral fracture incidence.17 In addition
to this, we found a significant association of the gain-of-function
polymorphism Ala348Thr to fracture incidence, where individuals
homozygous for the variant allele (AA) and thereby with gain of
receptor function were partially protected against vertebral fractures as
the incidence was reduced by almost 70% compared with subjects
homozygous for the wild-type allele (GG) (Figure 2).
To determine whether the detected differences could be attributed
to differences in confounding factors such as age, time since meno-
pause, daily calcium intake, intake of vitamin D, BMI, comparisons
by ANOVA were performed among the three genotypes for the
Ala348Thr polymorphism. No differences between groups for any of
the confounding factors could be demonstrated. A similar analysis
between fracture rate and Ala348Thr in the HRT group failed to show
significant association (data not shown).
Again, we grouped individuals carrying the rare allele (heterozygotes
and homozygotes for polymorphisms Val76Ala, Gly150Arg, Thr357Ser
and Ile568Asn). Now, as previously reported,17 we found an associa-
tion between reduced risk of vertebral fracture and the rare allele of
the Ile568Asn polymorphism. For the remaining three rare poly-
morphisms, no association to fracture risk could be demonstrated.
P2X7 risk model analyses – bone loss 5 and 10 years after
menopause
The results above suggest that several of the uncommon variants
confer a predisposition to accelerated loss of BMD. To further test this
hypothesis, we examined a risk model based on combining subjects
into one of three risk groups according to the functional effects
(Table 1) of the P2RX7 variants. The groupings are as follows: (A)
A ‘high-risk’ group consisting of individuals carrying one or more of
the variant alleles for any of the five total loss-of-function variants
(151+1g-4t, Gly150Arg, Arg276His, Arg307Gln and Ile568Asn). As
several of these alleles exert a dominant-negative effect if expressed
together with a gain-of-function allele, we allowed inclusion of a
Table 1 List of P2X7 receptor single-nucleotide polymorphisms for
which the participants in the Danish Osteoporosis Prevention Study
have been genotyped
rs number
Base
change
Amino acid
change
Minor allele
frequency
Functional
effect References
rs35933842 151+1g-t Null allele 0.01 gt .. 42,43
t 0
rs17525809 253T-C Val76Ala 0.06 TC NA 44
C ..
rs28360447 474G-A Gly150Arg 0.02 GA NA 44
A 0
rs208294 489C-T His155Tyr 0.43 CT m 45
T mm
rs7958311 835G-A Arg270His 0.25 GA 2 46
A 2
rs7958316 853G-A Arg276His 0.02 GA NA 30
A ..
rs28360457 946G-A Arg307Gln 0.01 GA .. 29,43
A 0
rs1718119 1068G-A Ala348Thr 0.39 GA NA 44–46
A mm
rs2230911 1096C-G Thr357Ser 0.09 CG . 33,44,45
G ..
rs2230912 1405A-G Gln460Arg 0.17 AG . 45
G .
rs3751143 1513A-C Glu496Ala 0.17 AC .. 44–51
C 0
rs1653624 1729T-A Ile568Asn 0.03 TA .. 37,44
A 0
Abbreviations: ., a minor reduction in receptor function (loss-of-function to 70–90% of
‘wild-type’ receptor); .., a major reduction in receptor function (loss-of-function to 10–70%
of ‘wild-type’ receptor); 0, total loss-of-function; m, a minor increase in receptor function
(receptor function between 110 and 130% of ‘wild-type’ receptor); mm, a major increase
in receptor function (receptor function above 130% of ‘wild-type’ receptor);2, no change
compared with ‘wild-type’ receptor; NA, not available (no data are published).
The nucleotide numbers in the table refer to the historical numbering (ref Buell), which has
been used in most publications until now. However, the reference from which the numbering
starts has recently been changed in the NCBI database. The historical numbering has been
used throughout this paper in order to be able to compare with previous studies in the field.
To determine the current NCBI number, the historical number should be subtracted by 26
nucleotides.
Furthermore, the table summarizes published effects on P2X7 receptor function of single-
nucleotide polymorphisms in the P2X7 receptor gene in isolation. The change can be either
in electrophysiological parameters, calcium influx or dye uptake/pore formation.
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co-inherited gain-of-function allele. (B) A ‘low-risk group’ consisting of
individuals homozygous for the Gln460Arg polymorphism, as we have
recently within the research consortium shown that it is an indicator
of the most pronounced increase in function of the receptor in
primary cells.30 These individuals are homozygous for the wild-type
allele of all five total loss-of-function variants detailed in group A and
thus do not carry any of the mutant alleles. (C) An ‘intermediate-risk’
group consisting of all other individuals.
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Figure 1 Relationship of P2X7 SNPs with changes in BMD. (a) Post-menopausal change in BMD in non-HRT individuals for the total loss-of-function SNP
Arg307Gln. Individuals carrying the mutant allele have an increased rate of bone loss. This is significant for the total hip (TH) 10 years after menopause,
and the same trend is present at the LS and FN (top panel). Furthermore, a similar trend is seen after the first 5 years after menopause (bottom panel). The
number of individuals with the two genotypes was 860 GG and 16 GA after 5 years and 758 GG and 15 GA after 10 years. No study participants were
homozygous for the variant A allele. (b) The presence of Arg307Gln variant, increases the rate of bone loss at the femoral neck (0–5 years) despite HRT
treatment. (c) Changes in BMD associated with the Ile568Asn variant over 5 years post menopause. Individuals homozygous for the variant allele (AA) have
significantly accelerated bone loss in the femoral neck, with the same trend seen at TH and LS. *P-value o0.05; LS, lumbar spine; FN, femoral neck;
NS, not significant; TH, total hip.
Table 2 Change in bone mineral density (BMD) for individuals not on
hormone replacement therapy
Arg307Gln GG GA P-value
Change in BMD 0–5 years (% per year)
N (876¼100 %) 860 (98.2) 16 (1.8)
BMD TH 0–5 years 0.94 (0.03) 1.17 (0.18) 0.33
BMD FN 0–5 years 1.23 (0.04) 1.71 (0.22) 0.09
BMD LS 0–5 years 1.28 (0.04) 1.53 (0.25) 0.30
Change in BMD 0–10 years (% per year)
N (773¼100%) 758 (98.1) 15 (1.9)
BMD TH 0–10 years 0.68 (0.02) 1.11 (0.17) 0.07
BMD FN 0–10 years 0.89 (0.02) 1.20 (0.13) 0.029
BMD LS 0–10 years 0.78 (0.03) 0.99 (0.21) 0.07
Abbreviations: FN, femoral neck; TH, total hip; LS, lumbar spine.
Bone loss is expressed in percent per year for the two genotypes for the Arg307Gln variant in
the P2X7 receptor. Mean values of BMD change in % per year (standard error of the mean).
Data are shown for all three anatomical sites.
Bold value indicates significant P-value.
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Figure 2 Association of fracture incidence with Ala348Thr variant in
non-HRT subjects. A w2-test was performed to test for differences in fracture
incidences between the three genotype groups 0–10 years post menopause.
Significantly fewer fractures are associated with homozygous mutant (AA)
group than the wild type (GG) or heterozygous (GA) group (P¼0.04). The
number of individuals with the genotype is shown below the bars. The
number of individuals having sustained a fracture is shown above each bar.
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As for the individual variants, we compared the baseline values of
age, height, BMI and markers of bone metabolism for the three risk-
groups. No statistically significant differences were found between
genotypes (Table 3). Next, baseline values of BMD at the lumbar
spine, femoral neck and total hip were compared using analysis of
covariance, with correction for logBMI, age and time since meno-
pause, and again no significant differences between groups could be
detected (Table 3).
We then tested whether there were any differences in rate of bone
loss between the three risk-groups for the untreated individuals. We
found a highly significant difference between the risk-groups for BMD
loss in the lumbar spine from baseline to 10 years after menopause.
Individuals belonging to the high-risk group lost more than twice as
much bone per year as the individuals in the low-risk group with the
intermediate-risk group showing bone loss at a rate between these two
extremes (Figure 3). Interestingly, the trend was the same for 0 to 5
years, although not significant, while a significant difference in bone
loss between risk groups from 5 to 10 years was found (P¼0.02)
clearly confirming that intact P2X7 receptor function is important
for maintaining a strong and healthy skeleton after menopause.
Haplotype analysis of P2X7 genotypes identified 17 haplotypes with
population frequencies 41.0 % (Table 4). Grouping the haplotypes
based on the haplotype blocks containing the 1068, 1096, 1405 and
1513 polymorphisms as described by Stokes et al30 showed similar
haplotype frequencies between the Australian cohort and the DOPS
cohort. Aggregating patients into a group of haplotypes carrying
‘high-risk’ loss-of-function variants showed the same accelerated
BMD loss as for the Group A defined above on the basis of SNPs
(data not shown).
Finally, the fracture risk between the risk-groups was determined
using w2-test. Although no significant differences could be detected
(data not shown), it should be noted that the small number of
individuals in each group reduced the power of the analysis.
DISCUSSION
This 10-year study shows that a SNP in the P2RX7 gene conferring
severe loss-of-function on the P2X7 receptor is associated with
accelerated bone loss in women following menopause. This variant
(Arg307Gln) is located in a coding region of the gene substituting an
uncharged glutamine in place of arginine-307 in the ATP-binding site
of the receptor thereby abolishing activation by agonist.29 Subjects
who were heterozygous for this Arg307Gln variant had440% greater
bone loss at the hip over the 0–10 years interval than subjects who
were wild type at this position. Estrogens have a strong anabolic effect
on bone mass and in this study estrogens reduced or even reversed
bone loss in all P2RX7 subgroups. However, the effect of the
Arg307Gln genotype to accelerate bone loss at the femoral neck was
evident even in subjects taking HRT continuously over the 0- to 5-year
period of study. Many of these subjects subsequently stopped HRT so
that numbers at 10 years became too small for analysis of this effect.
This observation suggests that the functional effects of polymorphisms
in the P2RX7 and estrogen receptor (ESR1) genes have independent
effects on bone mass. The association of low bone mass with the
Arg307Gln variant has been replicated in the Aberdeen Prospective
Osteoporosis Screening Study who studied 506 post-menopausal
women over 6- to 7-year follow-up.35 Subjects with the Arg307Gln
variant had lower BMD of the lumbar spine both at baseline and at
follow-up, suggesting this variant of the P2X7 receptor may be
exerting an effect on bone mass even before the menopause.35
The Arg307Gln has also been associated with other bone-related
events. A recent study showed an association of the Arg307Gln
polymorphism with increased failure rate for total hip replacement,36
although this is not necessarily the result of decreased bone mass.
Another polymorphism (Ile568Asn) in P2X7 showed a significant
association with changes in bone mass over 0–5 years. Subjects who
were heterozygous for Ile568Asn had more bone loss than those with
wild-type Ile-568, but as previously reported the difference did
not reach significance.17 Two subjects, however, were homozygous
for 568-Asn, which totally prevents trafficking of P2X7 to the cell
surface,37 and these two suffered major loss of BMD. Extensive
genotyping in 3430 Caucasian subjects has defined two haplotypes
(P2X7-2 and -4), which exhibit gain-of-function over wild type
(P2X7-1). Both P2X7-2 and P2X7-4 contain the Ala348Thr poly-
morphism and this variant is critical for the gain-of-function effect.30
Analysis showed a lesser fracture rate for subjects with one or two of
this gain-of-function allele.
Interestingly, we were able to identify three groups of individuals in
the cohort with highly different risk of developing osteoporosis based
Table 3 Baseline characteristics of the three risk-groups based on
P2X7 genotype
Risk group Low risk Intermediate risk High risk P-value
N (1635¼100%) 46 (2.8%) 1428 (87.3%) 161 (9.8%)
Age (years) 50.9 (0.4) 50.7 (0.1) 50.3 (0.2) 0.18
Height (cm) 164.8 (0.8) 164.5 (0.2) 164.3 (0.5) 0.85
BMI (kg/m2) 25.7 (0.6) 25.1 (0.1) 24.5 (0.3) 0.12
LS BMD (g/cm2) 1.050 (0.021) 1.024 (0.004) 1.018 (0.010) 0.50
FN BMD (g/cm2) 0.833 (0.018) 0.794 (0.003) 0.787 (0.007) 0.09
TH BMD (g/cm2) 0.940 (0.017) 0.916 (0.003) 0.908 (0.008) 0.54
Abbreviations: ANOVA, analysis of variance; ANCOVA, analysis of covariance; BMD, bone
mineral density; BMI, body mass index; FN, femoral neck; LS, lumbar spine; Low risk, gain-of-
function SNPs; High risk, loss-of-function SNPs; Intermediate risk, all other; TH, total hip.
Numbers are mean values with standard errors of the mean in parentheses. P-values are shown
for statistical ANOVA for age, height and BMI, while P-values are shown for ANCOVA for the
BMD parameters with age, BMI, and time since menopause as covariates.
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Figure 3 The rate of post-menopausal bone loss at the LS is associated with
P2X7 functional groupings. In the absence of HRT treatment women who
have one or more P2X7 loss-of-function SNP (high-risk group) have
significantly greater loss in BMD than women who have P2X7 gain-of-
function variants (low-risk group) and an intermediate group consisting of all
other individuals. **Po0.01.
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on their combined genotypes and the knowledge of functional effects
of these genotypes on P2X7 receptor function. The groups with the
lowest risk of developing osteoporosis were the ones homozygous for
the variant allele of the Gln460Arg polymorphism. However, in vitro
studies have shown that the variant allele in isolation reduces receptor
function slightly.45 In contrast cells transfected with the full haplotype
block has significantly increased function.30 Thus, the variant allele of
Gln460Arg is therefore likely to be co-inherited with other gain-of-
function polymorphisms in the P2X7 receptor, which subsequently are
associated with low risk of bone loss.
Recently, it was shown that the P2X4 receptor can be co-expressed
together with the P2X7 receptor and that P2X4 and P2X7 subunits can
form heteromeric channels.38 If this is the case in vivo, P2X4 receptor
subunits might theoretically replace ‘defect’ P2X7 receptor subunits
in the cell membrane thereby reducing the true effect of a genetic
defect in the gene encoding the P2X7 receptor. Furthermore, the P2X4
gene is situated close to and downstream for the P2X7 receptor on the
same chromosome. Thus, polymorphisms in the P2X7 gene might
be in linkage with polymorphisms in the P2X4 receptor gene.
The associations we find might therefore also be a consequence of
gain- or loss-of-function polymorphisms in the P2X4 gene. Thus, it is
highly warranted to investigate the association of P2X4 polymorph-
isms with bone status and also the interaction between P2X4 and
P2X7 polymorphisms.
In this study, loss-of-function polymorphisms in the human P2RX7
gene have produced analogous changes to deletion of the P2RX7 gene
in mice, which gave rise to animals with reduced BMD in weight-
bearing limbs because of reduced periosteal bone formation and
increased trabecular bone resorption.24 Similar skeletal changes have
been described in humans with disuse of weight-bearing limbs39
raising the possibility that the purinergic P2X7 receptor forms part
of a signaling pathway, which transduces mechanical strain into an
osteoblastic response and improved bone strength. Studies of osteo-
blasts and osteocytes in vitro have shown that fluid shear stresses
increase the production of prostaglandin E2 (PGE2) in wild type but
not in P2X7 –/– cells26 and PGE2 has been shown to have major
anabolic effects on bone formation. However, the first study to
demonstrate a direct link between P2X7 receptor activation and
osteogenesis was the study by Dixon’s group showing that activation
of P2X7 receptors in osteoblasts gives rise to the lipid mediators,
lysophosphatidic acid and PGE2,40 both of which have been reported
to regulate osteogenesis. Mechanical stimulation leads to a release of
nucleotides, which activate P2X7-mediated apoptosis of osteoclasts41
and thus lead to increased bone strength; an effect that would augment
the P2X7-induced osteogenesis.
We find that one of the polymorphisms (Gly150Arg) is not in
HWE. As we have genotyped the samples with two different methods
independently, genotyping error is not very likely. Other reasons could
be high mutation rate, selection toward one of the genotypes,
assortative mating, and so on. However, none of these seem very
likely, as only this polymorphism is not in HWE. Therefore, this is
likely to be a chance finding.
In conclusion, one uncommon P2X7 receptor variant, Arg307Gln,
exerted a dominant-negative effect on P2X7 function and heterozy-
gotes were associated with greater bone loss over 5 or 10 years than
wild types. A second uncommon variant, Ile568Asn, was present in
homozygous dosage in two subjects who exhibited the highest rate of
bone loss in our study. Our results for the Arg307Gln variant are
replicated in an independent cohort studied over 6 years in Aberdeen,
UK.35 and show that uncommon genetic variants of the P2X7 receptor
are an important risk factor in osteoporosis of post-menopausal women.
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Table 4 The table shows the 17 most frequent haplotypes (H1–H17) with a frequency of more than 1% in the cohort together with their
frequency and the predicted functional effects according to reference35
151+1 253 474 489 835 853 946 1068 1096 1405 1513 1729 N Frequency (%) Functional
H1 T T G C A G G G C A A T 567 16.20 WT
H2 T T G C G G G G C A A T 185 5.29 WT
H3 T T G T A G G G C A A T 155 4.43 WT
H4 T T G C G G G G C A A A 90 2.57 Loss
H5 T T G T G G G G C A A T 81 2.31 WT
H6 T T G T A A G G C A A T 49 1.40 Loss
H7 T T G C A G A G C A A T 37 1.06 Loss
H8 T T G C G G G A C A A T 537 15.34 Gain
H9 T C G C G G G A C A A T 159 4.54 Gain
H10 T T G T G G G A C A A T 84 2.40 Gain
H11 T T G T G G G G C A C T 412 11.77 Loss of pore
H12 T T G C G G G G C A C T 90 2.57 Loss of pore
H13 T T A T G G G G C A C T 36 1.03 Loss of pore
H14 T T G T G G G A C G A T 488 13.94 Gain
H15 T T G C G G G A C G A T 43 1.23 Gain
H16 T T G C G G G G G A A T 175 5.00 Loss
H17 T T G T G G G G G A A T 120 3.43 Loss
H1–H7 contains the haplotype block P2X7-1 described in by Stokes et al,30 while H8–H10 contains the P2X7-2 block, H11–H13 the P2X7-3 block, H14–H15 the P2X7-4 block and finally
H16–H17 the P2X7-5 haplotype block.
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